Bradley Rivotto

Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

M. Dimopoulos, J. Laubach, P. Richardson, 2019, American journal of hematology.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

J. Laubach, P. Richardson, S. Kroll, 2018, Clinical Cancer Research.

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

D. Auclair, A. Jakubowiak, J. Laubach, 2018, Blood.

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2018, Blood.

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

G. Ha, N. Munshi, J. Laubach, 2017 .

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

L. Trippa, P. Moreau, S. Minvielle, 2017, Blood.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

L. Trippa, M. Capelletti, S. Treon, 2018, Blood.